Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:50:03.603Z.
Calculation as of: 2026-10-06T19:50:03.603Z.
Quote observation: 2026-10-06T19:25:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 62e543f524ee8633d6080f2a553f9cbd6b945788c6a084cb4464cef9d8d253d7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2020-05-14.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
PRICE/FCF RATIO AVG TTM
N/A
PRICE/FCF RATIO AVG 3Y
N/A
PRICE/FCF RATIO AVG 5Y
N/A
PRICE/FCF RATIO AVG 10Y
N/A
PRICE/FCF RATIO AVG 15Y
N/A
PRICE/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$6.89M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.61M
Price/FCF Ratio
N/A
TTM Avg
1251.36
3Y Avg
3596.79
5Y Avg
3596.79
Market Cap
$7.08M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.67M
Price/FCF Ratio
N/A
TTM Avg
2104.37
3Y Avg
2470.51
5Y Avg
5857.68
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Exicure, Inc. (XCUR) | $6.82M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.87M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $6.89M | N/A | N/A | N/A | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.61M | N/A | 1251.36 | 3596.79 | 3596.79 |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $6.96M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.67M | N/A | 2104.37 | 2470.51 | 5857.68 |
| Aclarion, Inc. (ACON)vs › | $6.57M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.03M | N/A | 6.05 | 13.36 | 13.36 |
| Biomerica, Inc. (BMRA)vs › | $6.54M | N/A | 129.84 | 129.84 | 129.84 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/FCF RATIO |
|---|---|
| 2020-05-14 | 3854.33 |
| 2020-05-13 | 4051.15 |
| 2020-05-12 | 4411.98 |
| 2020-05-11 | 4362.78 |
| 2020-05-08 | 4198.76 |
| 2020-05-07 | 3903.54 |
| 2020-05-06 | 4051.15 |
| 2020-05-05 | 3690.32 |
| 2020-05-04 | 3395.09 |
| 2020-05-01 | 3067.06 |
| 2020-04-30 | 3460.70 |
| 2020-04-29 | 3559.11 |
| 2020-04-28 | 3608.31 |
| 2020-04-27 | 3542.71 |
| 2020-04-24 | 3575.51 |
| 2020-04-23 | 3608.31 |
| 2020-04-22 | 3526.30 |
| 2020-04-21 | 3559.11 |
| 2020-04-20 | 3247.48 |
| 2020-04-17 | 3362.29 |
| 2020-04-16 | 3198.28 |
| 2020-04-15 | 3132.67 |
| 2020-04-14 | 3181.87 |
| 2020-04-13 | 3263.88 |
| 2020-04-09 | 3198.28 |
| 2020-04-08 | 3001.46 |
| 2020-04-07 | 2640.63 |
| 2020-04-06 | 2312.60 |
| 2020-04-03 | 2230.59 |
| 2020-04-02 | 2214.19 |
| 2020-04-01 | 2312.60 |
| 2020-03-31 | 2427.41 |
| 2020-03-30 | 2246.99 |
| 2020-03-27 | 2164.99 |
| 2020-03-26 | 2230.59 |
| 2020-03-25 | 1968.17 |
| 2020-03-24 | 1738.55 |
| 2020-03-23 | 1771.35 |
| 2020-03-20 | 1689.35 |
| 2020-03-19 | 1705.75 |
| 2020-03-18 | 1689.35 |
| 2020-03-17 | 2050.18 |
| 2020-03-16 | 1869.76 |
| 2020-03-13 | 1951.77 |
| 2020-03-12 | 2148.59 |
| 2020-03-11 | 2722.63 |
| 2020-03-10 | 2903.05 |
